振东制药(300158) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥951,417,159.09, representing a 7.04% increase compared to ¥888,836,734.49 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥394,728.53, a decline of 104.31% from a profit of ¥9,149,858.74 in the previous year[5] - Total operating revenue for Q1 2023 was CNY 951,417,159.09, an increase of 7.06% compared to CNY 888,836,734.49 in the same period last year[21] - Operating profit for Q1 2023 decreased to CNY 7,304,228.83, down 59.5% from CNY 18,066,566.92 in the previous year[21] - The company reported a net loss attributable to shareholders of CNY 16,000,960.16, compared to a loss of CNY 15,606,231.63 in the previous year[19] - The net profit for Q1 2023 was -902,065.90 CNY, a significant decline compared to a net profit of 7,814,690.78 CNY in Q1 2022, representing a decrease of over 111%[22] - The company reported a total comprehensive income of -891,481.36 CNY for Q1 2023, compared to 7,815,211.37 CNY in Q1 2022, marking a decline of over 111%[22] Cash Flow and Investments - The net cash flow from operating activities was -¥221,509,803.49, a decrease of 410.50% compared to ¥71,339,618.63 in the same period last year[11] - The cash inflow from investment activities for Q1 2023 was 2,119,564,208.60 CNY, down from 6,080,578,426.29 CNY in Q1 2022, indicating a decrease of approximately 65%[25] - The cash outflow from investment activities was 1,760,902,169.05 CNY in Q1 2023, compared to 6,593,965,541.13 CNY in Q1 2022, reflecting a decrease of about 73%[25] - The net cash flow from financing activities for Q1 2023 was -110,972,152.16 CNY, compared to -22,104,128.34 CNY in Q1 2022, indicating a worsening situation[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,431,129,004.09, down 1.83% from ¥6,550,914,912.15 at the end of the previous year[5] - Total current assets decreased to CNY 4,761,788,679.00, down 2.5% from CNY 4,883,273,988.04 at the start of the year[19] - Total liabilities decreased to CNY 1,208,729,704.04, a reduction of 8.96% from CNY 1,327,624,130.74 at the beginning of the year[19] - Inventory increased to CNY 1,279,968,680.02, up 19.1% from CNY 1,074,458,576.25 at the beginning of the year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 74,948[13] - Shanxi Zhendong Health Industry Group Co., Ltd. holds 29.41% of the shares, amounting to 302,230,191 shares[13] - The top ten shareholders include institutional investors and individuals, with the largest being Shanxi Zhendong Health Industry Group Co., Ltd.[13] - The total number of restricted shares held by executives is 3,436,410, with 75,000 shares released during the period[15] - The company reported a total of 51,364,735 shares held by Zhongtai Securities Asset Management, representing 5.00% of the shares[13] - The report indicates that 2,850,000 shares are held by individual shareholder Liu Yubin, with no restrictions[13] - The company has not disclosed any related party relationships among the top shareholders[13] Other Financial Metrics - The company's financial expenses decreased by 135.97% to -¥972,391.69, attributed to a reduction in bank borrowings compared to the previous year[10] - The fair value change income for the period was ¥3,953,915.30, reflecting a substantial increase of 1,326.34% compared to the previous year[10] - The company reported a significant increase in investment income, which rose by 182.19% to ¥9,782,844.63 due to higher financial management returns[10] - Research and development expenses for Q1 2023 were CNY 48,885,568.66, a decrease of 6.1% compared to CNY 51,888,172.00 in Q1 2022[21] - The basic and diluted earnings per share for Q1 2023 were both -0.0004 CNY, compared to 0.0089 CNY in Q1 2022, reflecting a significant decline[22] Reporting Period - The financial report for Q1 2023 is prepared as of March 31, 2023[17] - The report does not mention any new product developments or market expansion strategies[16]